Evoke Pharma Inc Financials
Evoke Pharma Inc (EVOK) reported $10.2M in revenue for fiscal year 2024, up 97.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Commercialization overhead now dominates the model: sales growth is narrowing reported losses, but cash still comes from financing.
The latest year looks better on the income statement than on the cash-flow statement: sales rose sharply and losses narrowed, yet operating cash flow stayed near-$5.5M . With SG&A at$15.1M , the company is spending heavily to build commercial scale, so accounting progress is arriving before self-funding.
The cost structure no longer looks research-led. R&D fell to just
Year-end liquidity improved, with cash of
Financial Health Signals
Scored against emerging companies for FY2024. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Evoke Pharma Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Evoke Pharma Inc scores -9.76, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($8.1M) relative to total liabilities ($10.5M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Evoke Pharma Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Evoke Pharma Inc reported a net loss of $5.4M while operations used $5.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Evoke Pharma Inc reported an operating loss of $5.2M against $501K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Evoke Pharma Inc generated $10.2M in revenue in fiscal year 2024. This represents an increase of 97.8% from the prior year.
Evoke Pharma Inc reported -$5.4M in net income in fiscal year 2024. This represents an increase of 31.3% from the prior year.
Not reported for fiscal year 2024.
Cash & Balance Sheet
Evoke Pharma Inc held $13.6M in cash as of fiscal year 2024; long-term debt is not reported for that period.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
Evoke Pharma Inc's operating margin was -50.8% in fiscal year 2024, reflecting core business profitability. No change is given against fiscal year 2023: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Evoke Pharma Inc's net profit margin was -52.2% in fiscal year 2024, showing the share of revenue converted to profit. No change is given against fiscal year 2023: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Evoke Pharma Inc's ROE was -76.0% in fiscal year 2024, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2024.
Capital Allocation
Evoke Pharma Inc invested $16K in research and development in fiscal year 2024. This represents a decrease of 91.0% from the prior year.
Not reported for fiscal year 2024.
Not reported for fiscal year 2024.
EVOK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.4M | $10.2M+97.8% | $5.2M+106.5% | $2.5M+55.0% | $1.6M+6929.0% | $23K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $57K | $16K-91.0% | $182K-39.5% | $301K-49.1% | $590K-91.0% | $6.6M+91.9% | $3.4M-16.6% | $4.1M-42.6% | $7.1M+2.7% | $7.0M-14.7% | $8.2M-18.4% | $10.0M+944.1% | $957K | N/A | $1.8M | N/A |
| SG&A Expenses | $19.1M | $15.1M+23.3% | $12.2M+27.1% | $9.6M+8.7% | $8.9M+37.7% | $6.4M+72.0% | $3.7M-4.6% | $3.9M-4.2% | $4.1M+13.9% | $3.6M-1.9% | $3.7M+16.0% | $3.2M+92.0% | $1.6M | N/A | $571K | N/A |
| Operating Income | -$5.2M | -$5.2M+30.0% | -$7.4M+4.6% | -$7.8M+4.5% | -$8.2M+37.5% | -$13.0M-82.4% | -$7.2M+10.7% | -$8.0M+28.6% | -$11.2M-6.5% | -$10.5M+10.8% | -$11.8M+10.1% | -$13.2M-405.4% | -$2.6M | N/A | -$2.4M | N/A |
| Interest Expense | $500K | $501K+0.3% | $500K0.0% | $500K0.0% | $500K+342.5% | $113K | N/A | N/A | N/A | N/A | N/A | $108K-32.6% | $160K | N/A | N/A | N/A |
| Net Income | -$5.2M | -$5.4M+31.3% | -$7.8M-45.6% | -$5.4M+37.3% | -$8.5M+35.1% | -$13.2M-84.6% | -$7.1M+5.8% | -$7.6M+38.1% | -$12.2M-13.8% | -$10.7M+11.3% | -$12.1M+8.5% | -$13.2M-367.0% | -$2.8M | N/A | -$2.4M+52.4% | -$5.0M |
| EPS (Diluted) | — | -$2.81 | -$27.97 | -$2.62+17.6% | -$3.18 | N/A | N/A | -$0.46+48.9% | -$0.90+21.7% | -$1.15 | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
EVOK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $17.5M+147.8% | $7.1M-40.4% | $11.9M+12.1% | $10.6M+12.1% | $9.4M+47.5% | $6.4M+13.0% | $5.7M-28.7% | $7.9M-14.6% | $9.3M-2.5% | $9.5M-37.4% | $15.2M-39.0% | $25.0M+21437.6% | $116K | N/A | N/A |
| Current Assets | $17.2M+152.5% | $6.8M-41.8% | $11.7M+11.0% | $10.6M+13.8% | $9.3M+48.6% | $6.2M+10.6% | $5.6M-28.8% | $7.9M-14.6% | $9.3M-2.5% | $9.5M-37.4% | $15.2M-37.7% | $24.4M+20958.8% | $116K | N/A | N/A |
| Cash & Equivalents | $13.6M+186.9% | $4.7M-51.9% | $9.8M+7.6% | $9.1M+13.3% | $8.1M+42.5% | $5.7M+6.5% | $5.3M-30.7% | $7.7M-14.7% | $9.0M+3.6% | $8.7M-38.6% | $14.2M-41.5% | $24.2M+20756.9% | $116K-86.6% | $866K-78.6% | $4.0M |
| Inventory | $445K-7.6% | $482K+66.5% | $289K+56.0% | $186K-21.5% | $236K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $10.5M+8.6% | $9.6M+24.2% | $7.8M+10.7% | $7.0M-44.5% | $12.6M+527.7% | $2.0M+23.3% | $1.6M-71.7% | $5.8M+4.9% | $5.5M-9.2% | $6.1M+0.4% | $6.0M+58.9% | $3.8M-80.8% | $19.8M | N/A | N/A |
| Current Liabilities | $10.4M+7.6% | $9.6M+483.1% | $1.7M+17.7% | $1.4M-81.3% | $7.5M+274.0% | $2.0M+23.3% | $1.6M-21.2% | $2.1M+47.0% | $1.4M-23.0% | $1.8M-0.7% | $1.8M-19.1% | $2.3M+300.6% | $570K | N/A | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $4.2M+0.9% | $4.2M+177.6% | $1.5M+54.3% | $980K | N/A | N/A |
| Total Equity | $7.0M+372.8% | -$2.6M-163.2% | $4.1M+14.9% | $3.6M+210.6% | -$3.2M-173.4% | $4.4M+8.8% | $4.0M+85.9% | $2.2M-42.8% | $3.8M+9.3% | $3.5M-62.3% | $9.2M-56.6% | $21.2M+207.8% | -$19.7M-11.4% | -$17.7M-15.6% | -$15.3M |
| Retained Earnings | -$128.8M-4.3% | -$123.4M-6.7% | -$115.6M-7.7% | -$107.4M-8.6% | -$98.9M-15.3% | -$85.7M-9.1% | -$78.6M-10.7% | -$71.0M-20.8% | -$58.8M-22.4% | -$48.1M-33.7% | -$35.9M-58.4% | -$22.7M | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill.
EVOK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.3M | -$5.5M-9.5% | -$5.0M+24.4% | -$6.6M+46.6% | -$12.4M-86.3% | -$6.6M-15.1% | -$5.8M+17.4% | -$7.0M+19.9% | -$8.7M-0.1% | -$8.7M+17.0% | -$10.5M+8.7% | -$11.5M-278.3% | -$3.0M | N/A | -$2.9M | N/A |
| Financing Cash Flow | $3.6M | $14.3M+12100.3% | -$119K-101.6% | $7.3M-45.7% | $13.4M+48.6% | $9.0M+47.9% | $6.1M+32.2% | $4.6M-37.5% | $7.4M | N/A | N/A | N/A | $27.1M | N/A | -$278K | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
EVOK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -50.8% | -143.4% | -310.4% | -503.8% | -56678.3% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -52.2% | -150.4% | -213.4% | -527.7% | -57144.5% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -76.0% | N/A | -131.0%+109.1pp | -240.2% | N/A | -162.7%+25.3pp | -188.0%+376.7pp | -564.7%-280.9pp | -283.8%+66.0pp | -349.8%-205.7pp | -144.2%-130.8pp | -13.4% | N/A | N/A | N/A |
| Return on Assets | -30.6%+79.7pp | -110.2%-65.1pp | -45.2%+35.6pp | -80.8%+58.7pp | -139.4%-28.0pp | -111.4%+22.3pp | -133.7%+20.3pp | -154.0%-38.3pp | -115.7%+11.5pp | -127.2%-40.2pp | -87.0%-75.6pp | -11.3% | N/A | N/A | N/A |
| Current Ratio | 1.66+1.0x | 0.71-6.4x | 7.08-0.4x | 7.51+6.3x | 1.23-1.9x | 3.10-0.4x | 3.46-0.4x | 3.82-2.8x | 6.58+1.4x | 5.19-3.0x | 8.24-2.5x | 10.69+10.5x | 0.20 | N/A | N/A |
| Debt-to-Equity | 1.49 | N/A | 1.90-0.1x | 1.97 | N/A | 0.46+0.1x | 0.41-2.3x | 2.67+1.2x | 1.45+0.2x | 1.22+0.8x | 0.46+0.4x | 0.07 | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Similar Companies
Where Evoke Pharma Inc Ranks
Frequently Asked Questions
What is Evoke Pharma Inc's annual revenue?
Evoke Pharma Inc (EVOK) reported $10.2M in total revenue for fiscal year 2024. This represents a 97.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Evoke Pharma Inc's revenue growing?
Evoke Pharma Inc (EVOK) revenue grew by 97.8% year-over-year, from $5.2M to $10.2M in fiscal year 2024.
Is Evoke Pharma Inc profitable?
No, Evoke Pharma Inc (EVOK) reported a net income of -$5.4M in fiscal year 2024, with a net profit margin of -52.2%.
What is Evoke Pharma Inc's operating margin?
Evoke Pharma Inc (EVOK) had an operating margin of -50.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Evoke Pharma Inc's net profit margin?
Evoke Pharma Inc (EVOK) had a net profit margin of -52.2% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Evoke Pharma Inc's return on equity (ROE)?
Evoke Pharma Inc (EVOK) has a return on equity of -76.0% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Evoke Pharma Inc's operating cash flow?
Evoke Pharma Inc (EVOK) recorded an outflow of $5.5M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Evoke Pharma Inc's total assets?
Evoke Pharma Inc (EVOK) had $17.5M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Evoke Pharma Inc spend on research and development?
Evoke Pharma Inc (EVOK) invested $16K in research and development during fiscal year 2024.
What is Evoke Pharma Inc's current ratio?
Evoke Pharma Inc (EVOK) had a current ratio of 1.66 as of fiscal year 2024, which is generally considered healthy.
What is Evoke Pharma Inc's debt-to-equity ratio?
Evoke Pharma Inc (EVOK) had a debt-to-equity ratio of 1.49 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Evoke Pharma Inc's return on assets (ROA)?
Evoke Pharma Inc (EVOK) had a return on assets of -30.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Evoke Pharma Inc's Altman Z-Score?
Evoke Pharma Inc (EVOK) has an Altman Z-Score of -9.76, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Evoke Pharma Inc's Piotroski F-Score?
Evoke Pharma Inc (EVOK) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Evoke Pharma Inc's earnings high quality?
Evoke Pharma Inc (EVOK) reported a net loss of $5.4M while operations used $5.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Evoke Pharma Inc cover its interest payments?
Evoke Pharma Inc (EVOK) reported an operating loss of $5.2M against $501K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Evoke Pharma Inc?
Evoke Pharma Inc (EVOK) scores 62 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.